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Abstract
Background: Carbapenemase genes are one of the most frequent mechanisms reported in carbapenem-resistant
P. aeruginosa; however, description of P. aeruginosa co-harbouring two or more carbapenemases is unusual.
Methods: In this study we evaluated the presence of carbapenemase genes and the clonality of P. aeruginosa
isolates obtained from a hospital over a 12-year period. A total of 127 isolates of carbapenem-resistant P. aeruginosa
recovered from 109 patients feces (four samples), rectal swab (three samples), nasal swab (one sample) and anal abscess
(one sample), were evaluated. Minimum inhibitory concentrations of the following antibiotics imipenem, meropenem
and polymyxin E were determined by broth microdilution. The molecular profile of isolates was evaluated by pulsed field
gel electrophoresis (PFGE). PCR for the following carbapenemase genes blaIMP; blaSPM; blaVIM; blaSIM; blaNDM; blaKPC; blaGES
and nucleotide sequencing to confirm the enzyme gene types were performed and compared with the database
available on the Internet (BLAST-http://www.ncbi.nlm.nhi.gov/blast/).
Results: All isolates were carbapenem-resistant, their MIC50 and MIC90 were respectively 64 μg/mL and 256 μg/mL to
imipenem and 32 μg/mL and 256 μg/mL to meropenem, all isolates except one (MIC = 8 mg/L) were susceptible to
polymyxin E. The most frequent carbapenemase genes identified were blaSPM identified in 41 isolates (32%), followed by
10 with blakpc and 5 with blaVIM (3.9%). All belonged to the class SPM-1 and VIM-2. In 2011, one isolate harbouring three
carbapenemase genes (SPM-1, VIM-2 and KPC-2) that belonged to a new clone was identified in a hematopoietic stem
cell transplanted patient. Then, 19 carbapenem-resistant P. aeruginosa were identified in an outbreak that occurred in the
bone marrow transplant unit, all positive for SPM-1 gene, and 9 (47.3%) harbored both SPM-1 and KPC.
Conclusion: Our findings showed that PCR for KPC gene should be performed to evaluate carbapenem resistance in P.
aeruginosa and that this agent can harbor more than one carbapenemase gene. Attention should be focused on the
possible rapid spread of KPC in P. aeruginosa isolates and for the fact that P. aeruginosa may become a reservoir of this
transmissible resistance mechanism.
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Background
Carbapenem–resistant P. aeruginosa has become an im-
portant problem all over the world challenging the current
diagnostic approaches. Carbapenemase genes are one of
the most frequent mechanisms reported in carbapenem-
resistant P. aeruginosa [1-5]. It is important to identify
carbapenemase genes transmitted on mobile genetic ele-
ments which can lead to the spread of resistance of P. aer-
uginosa to carbapenem, which are the main drugs used to
treat infections caused by this agent. In Brazil, the most
common carbapenemase is the metallo-betalactamase,
SPM, however, recently P. aeruginosa harboring KPC was
identified [2].
In this study, we evaluated the presence of carbapene-
mase genes and the clonality of carbapenem- resistant P.
aeruginosa isolates obtained from a teaching hospital
over a 12-year period.
Methods
Study setting
The study was conducted in The Central Institute of Hos-
pital das Clinicas (ICHC – FMUSP), Brazil, a teaching hos-
pital with 1,000 beds, ten intensive care units totalizing 110
beds and a bone marrow transplant ward with 20 beds.
Isolates
A total of 129 P. aeruginosa carbapenem-resistant clinical
isolates identified over a 12-year period, from 1998 to
2012, recovered from 109 patients, hospitalized in the Clin-
ical and Surgical nursery, Intensive Care, Burned, Haema-
tology and Bone Marrow units at Hospital das Clinicas-
FMUSP were evaluated.
Susceptible profile
Minimum inhibitory concentrations (MICs) of imipe-
nem, meropenem and polymixin E were determined by
broth microdilution according with Clinical Laboratory
Standards Institute (CLSI 2012).
Molecular typing
Bacterial isolates were grown on blood agar overnight at
37°C. Gel blocks were made by using equal volumes of 2%
low-melting-point agar (BioRad, USA) and a bacterial sus-
pension of 9 × 108 cells. Genomic DNA was digested with
10U of XBAI (Fermentas, USA), [6] (Sekiguchi ref). DNAs
were separated by pulsed-field gel electrophoresis (PFGE)
using a CHEF-DR III system (Bio-Rad, USA). Running
conditions were 21 h at 14°C, with and initial switching
time of 1 s and final time of 30 s, at 6 V/cm. PFGE patterns
were interpreted according to Tenover et al. 1997 [7].
Carbapenemases genes
PCR for the following carbapenemase genes blaIMP; blaSPM;
blaVIM; blaSIM; blaNDM; blaKPC; blaGES was done as de-
scribed previously [8-11]. The following reference strains
were used as control in this study: P. aeruginosa that pro-
duced IMP-1, VIM-2, SIM-1, SPM-1 [10], KPC ATCC and
E. coli NDM. Nucleotide sequencing to confirm the enzyme
gene types was performed by MegaBACE 1000. The se-
quences were analyzed using the software Sequence
Analyzer with the Base Caller Cimarron 3.12. The genetic
sequence was compared with the database available on the
Internet (BLAST-http://www.ncbi.nlm.nhi.gov/blast/). The
KPC sequence was also comparing with KPC lahey data-
bases (http://www.lahey.org/Studies/other.asp#table1).
Results
All isolates were carbapenem-resistant, their MIC50 and
MIC90 were respectively 64 μg/mL and 256 μg/mL to
imipenem and 32 μg/mL and 256 μg/mL to meropenem.
All isolates except one (MIC: 8 μg/mL), were susceptible
to colistin, MICs varied from 0.25 to 2 μg/mL. They
1 – Molecular Weight; 2 , 3 – Negative Control; 4 – KPC Positive Contro l K. pneumonia ATCC (amplicon size 893bp) 5, 
6 and 7 – P. aeruginosa KPC positive
Figure 1 PCR for detection of SPM gene in P. aeruginosa carbapenem-resistant isolates. 1 - SPM Positive Control (amplicon size 798 bp). 2,
3 and 4 - P. aeruginosa SPM positive; 5, 6 - Negative Control and 6 - Molecular Weight.
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were recovered from blood (120 samples), feces (four
samples), rectal swab (three samples), nasal swab (one
sample) and anal abscess (one sample). PFGE showed
that, from 1998 to 2009, 25% (27 of 108 strains)
belonged to one predominant clone (A1), thirty-two
(A2) of 108 isolates (29.7%) were closely related to them
and sixteen (14.8%) were possibly related (A3, A4, A5,
A6 and A7) to the predominant clone (A1). Thirty-three
(30.5%) showed no relation with the predominant clone
A1. Among the 129 isolates 50 (39%) harboured a carbape-
nemase, the most frequent carbapenemase genes identified
were blaSPM identified in 41 isolates (32%) (Figure 1),
followed by 10 with blakpc (Figure 2) and 5 with blaVIM
(Figure 3). GES-5 was identified only in 3 isolates from one
burned patient. Pseudomonas aeruginosa harbouring SPM-
1 was identified for the first time in the Bone Marrow
Transplant unit in 1998, VIM-2 in the Emergency Room in
2001 and GES-5 in the Burned Intensive Care Unit. Gen-
Bank accession numbers: JX840596 (VIM-2), JX682700-
JX682705 (KPC-2) and JX870518-JX870528 (SPM-1).
In 2012 during an outbreak that occurred in the bone
marrow transplant unit, 19 carbapemem-resistant P.
aeruginosa were identified (clone K, L, L1, L2, L3 and
M), all positive for SPM-1 gene, and 10 (47.3%) har-
boured both SPM-1 and KPC-2. The majority of the
KPC, six isolates of nine, belong to the clone of the out-
break (K).
The relation between molecular profile and carbapene-
mase gene for all period is shown on Table 1.
Discussion
It is the first report of P. aeruginosa co-harbouring blaKPC
and blaSPM genes and the first report in Brazil of P. aerugi-
nosa carrying KPC-2, VIM-2 and SPM-1. SPM-1 was the
most frequent carbapenemase identified in our hospital,
followed by KPC-2. KPC in P. aeruginosa is rare and occurs
mainly in the American continent [1-5,12]. Recently, P.
aeruginosa harbouring KPC was described in Argentina
[13] and Iran [14], showing the potential rapid dissemin-
ation of this mechanism of resistance to the world.
1, 6 – Molecular Weight; 2 – VIM Positive Control; (amplicon size 382bp) 3, 4 – P. aeruginosa VIM positive and 5 -
Negative Control
Figure 2 PCR for detection KPC gene in P. aeruginosa carbapenem-resistant isolates. 1 – Molecular Weight; 2, 3 – Negative Control; 4 – KPC
Positive Control (amplicon size 893 bp); 5, 6 and 7 – P. aeruginosa KPC positive.
1 - SPM Positive Control; 2, 3 and 4 - P. aeruginosa SPM positive (amplicon size 798bp ; 5, 6 - Negative 
Control and 6 - Molecular Weight
Figure 3 PCR for detection of VIM gene in P. aeruginosa carbapenem-resistant isolates. 1, 6 – Molecular Weight; 2 – VIM Positive Control
(amplicon size 382 bp); 3, 4 – P. aeruginosa VIM positive and 5 - Negative Control.
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Even though P. aeruginosa harbouring KPC was identi-
fied in 2010 in Brazil [2], no other report was published
since then.
Only 50 of 129 P. aeruginosa carbapenem-resistant har-
boured a carbapenemase evaluated in this study. Thus, the
carbapenem resistance could be related to other mechanism
of resistance such as outer-membrane protein alteration, ef-
flux system overexpression or new carbapenemase not yet
identified [15-17].
Pseudomonas aeruginosa co-harbouring carbapenemase
is uncommon; there are few reports in the literature
[1;3]. Pseudomonas aeruginosa isolate co-harbouring
KPC and a metallo-β-lactamase (IMP-8) was recently re-
ported in Puerto Rico [3] and isolates co-harbouring
KPC and VIM gene were identified in Colombia [1]. We
described a new clone of P. aeruginosa co-harbouring
SPM-1 and KPC-2 that caused an outbreak in a Bone Mar-
row transplantation unit, and an isolate co-harbouring
three carbapenemase (SPM-1; KPC-2 and VIM-2) that
belonged to a different clone then previous described in
two outbreaks that occurred in this unit and were con-
trolled with reinforcement of hand hygiene and contact
precautions, one due to P. aeruginosa harbouring SPM-1
and other harbouring VIM-2 [18].
This P. aeruginosa isolate harbouring KPC-2 was iden-
tified for the first time in our hospital in 2011 in a
hematopoietic stem cell transplanted patient. It har-
boured three carbapanemase genes (SPM-1, VIM-2 and
KPC-2), and belonged to a new clone (JA) not identified
before in the hospital. This isolate showed a resistant
profile to both imipenem and meropenem with MIC of
64 μg/mL and 32 μg /mL, respectively, but was suscep-
tible to polymyxin and colistin with a MIC of 2 μg /mL
for both drugs.
In 2012 during an outbreak that occurred in the Bone
Marrow Transplant unit, 19 carbapemem-resistant P. aer-
uginosa were identified (clone K, L, L1, L2, L3 and M), all
positive for SPM-1 gene, and 10 (47.3%) harbored both
SPM-1 and KPC-2. The majority of the KPC, six isolates
of ten, belong to the clone of the outbreak (KB). Our data
showed different clones circulating in our hospital and a
new one predominate clone harboring KPC. A recent
study also described dissemination of a new clone of P.
aeruginosa harbouring KPC in a hospital in Argentina
after a K. pneumonia-KPC positive outbreak [13].
Other interesting findings of our study are that GES-5
was restricted to the Burned Intensive Care Unit and
was identified only in 2001. VIM-1 was first identified in
the Emergency Room and then in the Bone Marrow
Transplant Unit, and SPM is spread in different units in
the hospital. These results were similar with previous
Brazilian reports that showed that SPM-1 is endemic in
several hospitals in the country [19,20].
The complete sequence of two KPC-harbouring plas-
mids, Plasmid pCOL-1 (31529 bp), IncP-6 replicon
group and Plasmid pPA-2 (7995 bp) from P. aeruginosa
showed that they differing in size and in incompatibility
group, and harbouring different genetic structures con-
taining the blaKPC-2 genes [21]. These findings suggest
that the carbapenemase resistance dissemination due to
KPC in P. aeruginosa will be similar to that seen in En-
terobacteriaceae. Thus, it is very important to under-
stand the epidemiology of these multiresistant isolates,
Table 1 Carbapenemase genes and clonality of 129
carbapenem-resistant P. aeruginosa isolated in Hospital
das Clinicas, over a 12-year period
Carbapenemase gene Number of
isolates
PFGE
clone
Year of
identification
None (n = 79) 27 A1 1998-2008
25 A2
2 A3
5 A5
8 B
6 C
2 D
2 E
2 F
SPM-1 (n = 33) 7 A2
3 A3
1 A4
1 A6
1 A7
6 G 1998-2012
2 I
6 L
2 L1
1 L2
1 L3
2 M
VIM-2 (n = 4) 1 B
1 D
2 H 2001-2009
GES-5 (n = 3) 3 A5
2001
SPM-1 and KPC-2 (n = 9)
6 KB
1 LC
1 L1D 2012
1 ME
SPM-1 and VIM-2 and
KPC-2 (n = 1)
1 JA 2011
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in order to achieve early implementation of adequate con-
trol measures to contain and reduce their dissemination in
the hospital setting. Pseudomonas aeruginosa can acquired
this transmissible resistance mechanism, going unnoticed
and be a source of spread of KPC to other genus and spe-
cies of bacteria. Besides carbapenem-resistance in P. aeru-
ginosa can be due to two or more carbapenemase genes,
including KPC-gene.
In conclusion, our findings showed that SPM-1 is the
most frequent carbapenemase identified in our hospital,
followed by KPC-2. Thus, PCR for KPC gene should be
performed to evaluate carbapenem resistance in P. aeru-
ginosa and this agent can harbor more than one carba-
penemase gene. Attention should be focused on the
possible rapid spread of KPC in P. aeruginosa isolates
and for the fact that P. aeruginosa may become a reser-
voir of this transmissible resistance mechanism.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
Concept and design (SFC), data collection and laboratory work (CR, LF, JR,
GL, LCS) data analysis and interpretation (CR, ASL, SFC), drafting of the
manuscript (CR,TG, ASL, SFC), critical review of the manuscript (CR, TG, SL,
SFc), final approval of manuscript for publication (CR, LF, JR, GL, LCS,TG, ASl,
SFC). All authors read and approved the final manuscript.
Funding section
This study was performed using internal funding.
Author details
1Laboratory of Bacteriology of Department of Infectious, Diseases of
University of São Paulo, Dr. Eneas Carvalho de Aguiar 470, São Paulo Zip
Code 02461011, Brazil. 2Department of Infectious, Diseases of University of
São Paulo, Dr. Eneas Carvalho de Aguiar 470, São Paulo Zip Code 02461011,
Brazil. 3Laboratory of Microbiology of Hospital das Clinicas of University of
São Paulo, Dr. Eneas Carvalho de Aguiar 255, São Paulo Zip Code 02461011,
Brazil.
Received: 22 April 2014 Accepted: 20 August 2014
References
1. Correa A, Montealegre MC, Mojica MF, Maya JJ, Rojas LJ, De La Cadena EP, Ruiz
SJ, Recalde M, Rosso F, Quinn JP, Villegas MV: First report of a pseudomonas
aeruginosa isolate co-harboring KPC and VIM carbapenemases. Antimicrob
Agents Chemother 2012, 56(10):5422–5423.
2. Jácome PR, Alves LR, Cabral AB, Lopes AC, Maciel MA: First report of KPC-
producing pseudomonas aeruginosa in Brazil. Antimicrob Agents
Chemother 2012, 56(9):4990.
3. Martínez T, Vázquez GJ, Aquino EE, Ramírez-Ronda R, Robledo IE: First
report of a Pseudomonas aeruginosa clinical isolate co-harboring KPC-2
and IMP-18 carbapenemases. Int J Antimicrob Agents 2012, 39(6):542–543.
4. Cuzon G, Naas T, Villegas MV, Correa A, Quinn JP, Nordmann P: Wide
dissemination of Pseudomonas aeruginosa producing beta-lactamase
blaKPC-2 gene in Colombia. Antimicrob Agents Chemother 2011,
55(11):5350–5353.
5. Villegas MV, Lolans K, Correa A, Kattan JN, Lopez JA, Quinn JP, Colombian
Nosocomial Resistance Study Group: First identification of Pseudomonas
aeruginosa isolates producing a KPC-type carbapenem-hydrolyzing beta-
lactamase. Antimicrob Agents Chemother 2007, 51(4):1553–1555.
6. Sekiguchi J, Asagi T, Miyoshi-Akiyama T, Fujino T, Kobayashi I, Morita K,
Kikuchi Y, Kuratsuji T, Kirikae T: Multidrug-resistant Pseudomonas
aeruginosa strain that caused an outbreak in a neurosurgery ward and
its aac(6')-Iae gene cassette encoding a novel aminoglycoside
acetyltransferase. Antimicrob Agents Chemother 2005, 49(9):3734–3742.
7. Tenover F, Arbeit RD, Goering RV, Mickelsen PA, Murray BE, Persing DH,
Swaminathan B: Interpreting chromosomal DNA restriction patterns
produced by pulsed-field gel electrophoresis: criteria for bacterial strains
typing. J Clin Microbiol 1995, 33(9):2233–2239.
8. Bradford PA, Bratu C, Urban C, Visalli M, Mariano N, Landman D, Rahal JJ,
Brooks S, Cebular S, Quale J: Emergence of carbapenem-resistant
Klebsiella species possessing the class A carbanem hydrolyzing KPC-2
and Inhibithor-resitant TEM30 β-lactamases in New York. Clin Infect Dis
2004, 39(1):55–60.
9. Chen Y, Zhou Z, Zang Y, Yu Y: Emergence of NDM-1 producing Acinetobacter
baumannii in China. J Antimicrob Chemother 2011, 66(6):1255–1259.
10. Mendes ER, Kiyota KA, Monteiro J, Castanheira M, Andrade SS, Gales AC,
Pignatari AC, Tufik S: Rapid detection and identification of Metallo-β-
lactamase- encoding genes by multiplex real time PCR assay and melt
curve analysis. J Clin Microbiol 2007, 45(2):544–547.
11. Kim SY, Park YJ, Yu JK, Kim HS, Park YS, Yoon JB, Yoo JY, Lee K: Prevalence
and mechanisms of decreased susceptibility to carbapenems in Klebsiella
pneumoniae isolates. Diagn Microbiol Infect Dis 2007, 57(1):85–91.
12. García Ramírez D, Nicola F, Zarate S, Relloso S, Smayevsky J, Arduino S:
Emergence of Pseudomonas aeruginosa with KPC-type carbapenemase in
a teaching hospital: an 8-year study. J Med Microbiol 2013, 62:1565–1570.
13. Santella G, Cittadini R, Papalia M, Vera Ocampo C, Del Castillo M, Vay C, Gutkind
G, Radice M: First clonal spread of KPC-producing Pseudomonas aeruginosa
in Buenos Aires, Argentina. Infect Genet Evol 2012, 12(8):2003–2005.
14. Lari AR, Azimi L, Rahbar M, Alaghehbandan R, Sattarzadeh-Tabrizi M: First
report of Klebsiella pneumonia carbapenemase-producing Pseudomonas
aeruginosa isolated from burn patients in Iran: phenotypic and
genotypic methods. GMS Hyg Infect Control 2014, 9(1):Doc06.
15. Liu Y, Li XY, Wan LG, Jiang WY, Li FQ, Yang JH: Efflux system
overexpression and decreased OprD contribute to the carbapenem
resistance among extended-spectrum beta-lactamase-producing
Pseudomonas aeruginosa isolates from a Chinese university hospital.
Microb Drug Resist 2013, 19(6):463–468.
16. Castanheira M, Deshpande LM, Costello A, Davies TA, Jones RN:
Epidemiology and carbapenem resistance mechanisms of carbapenem-
non-susceptible Pseudomonasaeruginosa collected during 2009–11 in
14 European and Mediterranean countries. J Antimicrob Chemother 2014,
69(7):1804–1814.
17. Aghazadeh M, Hojabri Z, Mahdian R, Nahaei MR, Rahmati M, Hojabri T,
Pirzadeh T, Pajand O: Role of efflux pumps: MexAB-OprM and MexXY
(−OprA), AmpC cephalosporinase and OprD porin in non-metallo-
β-lactamase producing Pseudomonas aeruginosa isolated from cystic
fibrosis and burn patients. Infect Genet Evol 2014, 24:187–192.
18. Paez J, Levin AS, Fu L, Basso M, Fonseca GH, Dulley FL, Rossi F, Guimarães T,
Costa SF: Clusters of infection due to metallo-β-lactamase-producing
Pseudomonas aeruginosa in stem cell transplant and haematology units.
J Hosp Infect 2011, 77(1):76–77.
19. Camargo CH, Bruder-Nascimento A, Mondelli AL, Montelli AC, Sadatsune T:
Detection of SPM and IMP metallo-β-lactamases in clinical specimens of
Pseudomonas aeruginosa from a Brazilian public tertiary hospital.
Braz J Infect Dis 2011, 15(5):478–481.
20. Scheffer MC, Gales AC, Barth AL, Carmo Filho JR, Dalla-Costa LM:
Carbapenem-resistant Pseudomonas aeruginosa: clonal spread in
southern Brazil and in the state of Goiás. Braz J Infect Dis 2010,
14(5):508–509.
21. Naas T, Bonnin RA, Cuzon G, Villegas MV, Nordmann P: Complete sequence
of two KPC-harbouring plasmids from Pseudomonas aeruginosa.
J Antimicrob Chemother 2013, 68(8):1757–1762.
doi:10.1186/s12941-014-0043-3
Cite this article as: Rizek et al.: Characterization of carbapenem-resistant
Pseudomonas aeruginosa clinical isolates, carrying multiple genes
coding for this antibiotic resistance. Annals of Clinical Microbiology and
Antimicrobials 2014 13:43.
Rizek et al. Annals of Clinical Microbiology and Antimicrobials 2014, 13:43 Page 5 of 5
http://www.ann-clinmicrob.com/content/13/1/43
